{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:04:08Z","timestamp":1793829848262,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974006"],"award-info":[{"award-number":["81974006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014137","name":"Shanghai Shenkang Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2020CR2070B"],"award-info":[{"award-number":["SHDC2020CR2070B"]}],"id":[{"id":"10.13039\/501100014137","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06068-3","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T14:52:32Z","timestamp":1736779952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Targeting deubiquitinase USP7-mediated stabilization of XPO1 contributes to the anti-myeloma effects of selinexor"],"prefix":"10.1186","volume":"23","author":[{"given":"Junying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yike","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2813-5850","authenticated-orcid":false,"given":"Jian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"issue":"5","key":"6068_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377.","journal-title":"JAMA"},{"key":"6068_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102284","volume":"100","author":"P Rodriguez-Otero","year":"2021","unstructured":"Rodriguez-Otero P, Paiva B, San-Miguel JF. Roadmap to cure multiple myeloma. Cancer Treat Rev. 2021;100: 102284.","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"6068_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","volume":"10","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10(9):94.","journal-title":"Blood Cancer J"},{"issue":"3","key":"6068_CR4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","volume":"18","author":"AS Azmi","year":"2021","unstructured":"Azmi AS, Uddin MH, Mohammad RM. The nuclear export protein XPO1\u2014from biology to targeted therapy. Nat Rev Clin Oncol. 2021;18(3):152\u201369.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"6068_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrm4010","volume":"16","author":"VO Wickramasinghe","year":"2015","unstructured":"Wickramasinghe VO, Laskey RA. Control of mammalian gene expression by selective mRNA export. Nat Rev Mol Cell Biol. 2015;16(7):431\u201342.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"6068_CR6","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1261\/rna.060137.116","volume":"23","author":"L Volpon","year":"2017","unstructured":"Volpon L, Culjkovic-Kraljacic B, Sohn HS, et al. A biochemical framework for eIF4E-dependent mRNA export and nuclear recycling of the export machinery. RNA (New York, NY). 2017;23(6):927\u201337.","journal-title":"RNA (New York, NY)"},{"issue":"1","key":"6068_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-017-0412-4","volume":"10","author":"V Camus","year":"2017","unstructured":"Camus V, Miloudi H, Taly A, et al. XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy. J Hematol Oncol. 2017;10(1):47.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"6068_CR8","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1158\/2159-8290.CD-19-0298","volume":"9","author":"J Taylor","year":"2019","unstructured":"Taylor J, Sendino M, Gorelick AN, et al. Altered nuclear export signal recognition as a driver of oncogenesis. Cancer Discov. 2019;9(10):1452\u201367.","journal-title":"Cancer Discov"},{"issue":"1","key":"6068_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-016-0304-z","volume":"9","author":"JG Turner","year":"2016","unstructured":"Turner JG, Dawson JL, Grant S, et al. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol. 2016;9(1):73.","journal-title":"J Hematol Oncol"},{"issue":"48","key":"6068_CR10","doi-asserted-by":"publisher","first-page":"78896","DOI":"10.18632\/oncotarget.12969","volume":"7","author":"JG Turner","year":"2016","unstructured":"Turner JG, Kashyap T, Dawson JL, et al. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of I\u03baB\u03b1 and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget. 2016;7(48):78896\u2013909.","journal-title":"Oncotarget"},{"issue":"1","key":"6068_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-020-00903-4","volume":"13","author":"NG Azizian","year":"2020","unstructured":"Azizian NG, Li Y. XPO1-dependent nuclear export as a target for cancer therapy. J Hematol Oncol. 2020;13(1):61.","journal-title":"J Hematol Oncol"},{"issue":"19","key":"6068_CR12","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2217\/fon-2020-0054","volume":"16","author":"S Richard","year":"2020","unstructured":"Richard S, Richter J, Jagannath S. Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma. Future Oncol. 2020;16(19):1331\u201350.","journal-title":"Future Oncol"},{"issue":"10262","key":"6068_CR13","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"396","author":"S Grosicki","year":"2020","unstructured":"Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020;396(10262):1563\u201373.","journal-title":"Lancet"},{"issue":"1","key":"6068_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12916-022-02305-4","volume":"20","author":"L Qiu","year":"2022","unstructured":"Qiu L, Xia Z, Fu C, et al. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed\/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study. BMC Med. 2022;20(1):108.","journal-title":"BMC Med"},{"issue":"12","key":"6068_CR15","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1038\/leu.2016.136","volume":"30","author":"ZA Hing","year":"2016","unstructured":"Hing ZA, Fung HY, Ranganathan P, et al. Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies. Leukemia. 2016;30(12):2364\u201372.","journal-title":"Leukemia"},{"issue":"20","key":"6068_CR16","doi-asserted-by":"publisher","first-page":"5614","DOI":"10.1158\/0008-5472.CAN-17-1323","volume":"77","author":"F Conforti","year":"2017","unstructured":"Conforti F, Zhang X, Rao G, et al. Therapeutic effects of XPO1 inhibition in thymic epithelial tumors. Cancer Res. 2017;77(20):5614\u201327.","journal-title":"Cancer Res"},{"key":"6068_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114305","volume":"160","author":"B Kwanten","year":"2023","unstructured":"Kwanten B, Deconick T, Walker C, et al. E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1. Biomed Pharmacother. 2023;160: 114305.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"6068_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3724\/SP.J.1005.2012.00005","volume":"34","author":"K Chen","year":"2012","unstructured":"Chen K, Cheng HH, Zhou RJ. Molecular mechanisms and functions of autophagy and the ubiquitin-proteasome pathway. Yi Chuan. 2012;34(1):5\u201318.","journal-title":"Yi Chuan"},{"issue":"12","key":"6068_CR19","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1182\/bloodadvances.2021006638","volume":"7","author":"S Li","year":"2023","unstructured":"Li S, Fu J, Walker CJ, et al. Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects. Blood Adv. 2023;7(12):2926\u201337.","journal-title":"Blood Adv"},{"key":"6068_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108722","volume":"108","author":"F Hu","year":"2022","unstructured":"Hu F, Chen XQ, Li XP, et al. Drug resistance biomarker ABCC4 of selinexor and immune feature in multiple myeloma. Int Immunopharmacol. 2022;108: 108722.","journal-title":"Int Immunopharmacol"},{"key":"6068_CR21","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.41331","volume":"8","author":"Y Li","year":"2019","unstructured":"Li Y, Zhou J, Min S, et al. Distinct RanBP1 nuclear export and cargo dissociation mechanisms between fungi and animals. Elife. 2019;8: e41331.","journal-title":"Elife"},{"issue":"12","key":"6068_CR22","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1158\/1535-7163.MCT-14-0064","volume":"13","author":"N Saito","year":"2014","unstructured":"Saito N, Sakakibara K, Sato T, et al. CBS9106-induced CRM1 degradation is mediated by cullin ring ligase activity and the neddylation pathway. Mol Cancer Ther. 2014;13(12):3013\u201323.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"6068_CR23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/cancers12020407","volume":"12","author":"V Pinto","year":"2020","unstructured":"Pinto V, Bergantim R, Caires HR, et al. Multiple myeloma: available therapies and causes of drug resistance. Cancers (Basel). 2020;12(2):407.","journal-title":"Cancers (Basel)."},{"key":"6068_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1146\/annurev-med-050522-033815","volume":"75","author":"AL Garfall","year":"2024","unstructured":"Garfall AL. New biological therapies for multiple myeloma. Annu Rev Med. 2024;75:13\u201329.","journal-title":"Annu Rev Med"},{"key":"6068_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100758","volume":"46","author":"K Benkova","year":"2021","unstructured":"Benkova K, Mihalyova J, Hajek R, et al. Selinexor, selective inhibitor of nuclear export: unselective bullet for blood cancers. Blood Rev. 2021;46: 100758.","journal-title":"Blood Rev"},{"issue":"21","key":"6068_CR26","doi-asserted-by":"publisher","first-page":"15534","DOI":"10.1021\/acs.jmedchem.1c01145","volume":"64","author":"S Liu","year":"2021","unstructured":"Liu S, Qiao W, Sun Q, et al. Chromosome region maintenance 1 (XPO1\/CRM1) as an anticancer target and discovery of its inhibitor. J Med Chem. 2021;64(21):15534\u201348.","journal-title":"J Med Chem"},{"issue":"1","key":"6068_CR27","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.1002\/ajh.26010","volume":"96","author":"R Cornell","year":"2021","unstructured":"Cornell R, Hari P, Tang S, et al. Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. Am J Hematol. 2021;96(1):E5-e8.","journal-title":"Am J Hematol"},{"issue":"3","key":"6068_CR28","doi-asserted-by":"publisher","first-page":"E83","DOI":"10.1002\/ajh.26434","volume":"97","author":"S Delimpasi","year":"2022","unstructured":"Delimpasi S, Mateos MV, Auner HW, et al. Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. Am J Hematol. 2022;97(3):E83\u20136.","journal-title":"Am J Hematol"},{"issue":"11","key":"6068_CR29","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1038\/s41375-020-0958-y","volume":"34","author":"B Nachmias","year":"2020","unstructured":"Nachmias B, Schimmer AD. Targeting nuclear import and export in hematological malignancies. Leukemia. 2020;34(11):2875\u201386.","journal-title":"Leukemia"},{"issue":"1","key":"6068_CR30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/leu.2013.115","volume":"28","author":"YT Tai","year":"2014","unstructured":"Tai YT, Landesman Y, Acharya C, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28(1):155\u201365.","journal-title":"Leukemia"},{"key":"6068_CR31","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.23961","volume":"6","author":"HY Fung","year":"2017","unstructured":"Fung HY, Fu SC, Chook YM. Nuclear export receptor CRM1 recognizes diverse conformations in nuclear export signals. Elife. 2017;6: e23961.","journal-title":"Elife"},{"issue":"11","key":"6068_CR32","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3390\/ph14111131","volume":"14","author":"M Gargantilla","year":"2021","unstructured":"Gargantilla M, L\u00f3pez-Fern\u00e1ndez J, Camarasa MJ, et al. Inhibition of XPO-1 mediated nuclear export through the michael-acceptor character of chalcones. Pharmaceuticals (Basel, Switzerland). 2021;14(11):1131.","journal-title":"Pharmaceuticals (Basel, Switzerland)."},{"issue":"3","key":"6068_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188903","volume":"1878","author":"G Saha","year":"2023","unstructured":"Saha G, Roy S, Basu M, et al. USP7\u2014a crucial regulator of cancer hallmarks. Biochim Biophys Acta Rev Cancer. 2023;1878(3): 188903.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"6068_CR34","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3389\/fcell.2020.00717","volume":"8","author":"GJ Valles","year":"2020","unstructured":"Valles GJ, Bezsonova I, Woodgate R, et al. USP7 is a master regulator of genome stability. Front Cell Dev Biol. 2020;8:717.","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"6068_CR35","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/14728222.2023.2266571","volume":"27","author":"LD Carreira","year":"2023","unstructured":"Carreira LD, Oliveira RI, Moreira VM, et al. Ubiquitin-specific protease 7 (USP7): an emerging drug target for cancer treatment. Expert Opin Ther Targets. 2023;27(11):1043\u201358.","journal-title":"Expert Opin Ther Targets"},{"issue":"14","key":"6068_CR36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI146893","volume":"131","author":"C Li","year":"2021","unstructured":"Li C, Xia J, Franqui-Machin R, et al. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies. J Clin Invest. 2021;131(14): e146893.","journal-title":"J Clin Invest"},{"key":"6068_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104961","volume":"100","author":"P Tang","year":"2024","unstructured":"Tang P, Yu Z, Sun H, et al. CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy. EBioMedicine. 2024;100: 104961.","journal-title":"EBioMedicine"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06068-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06068-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06068-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T14:52:35Z","timestamp":1736779955000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06068-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6068"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06068-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine (Ethics Approval Number: KY2020-191).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors have declared that they agree to publish.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}